TOCILIZUMAB AMELIORATES VASCULAR INFLAMMATION AND CLINICAL SYMPTOMS IN PATIENTS WITH TAKAYASU ARTERITIS REFRACTOTRY TO GLUCOCORTICOIDS  by Nakaoka, Yoshikazu et al.
E2026
JACC March 12, 2013
Volume 61, Issue 10
Vascular Medicine 
TocilizumaB amelioraTes vascular inflammaTion and clinical sympToms in paTienTs wiTh 
Takayasu arTeriTis refracToTry To glucocorTicoids
Poster Contributions
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.-10:45 a.m.
Session Title: Atherosclerosis, Inflammation, Biomarkers and Outcomes: What’s New?
Abstract Category: 35. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1124-161
Authors: Yoshikazu Nakaoka, Kaori Higuchi, Yoh Arita, Takahiro Kataoka, Taku Yasui, Kuniyasu Ikeoka, Tomohito Ohtani, Yasushi Sakata, Keiko 
Yamauchi-Takihara, Issei Komuro, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Background: Treatment of refractory Takayasu arteritis (TA) remains a challenging clinical issue. Patients usually respond to glucocorticoid (GC) 
therapy, but often relapse on tapering of the GC dose. Additionally, GCs therapy is accompanied with a variety of adverse events. The aim of this study 
was to assess the efficacy and safety of the interleukin-6 (IL-6) receptor (IL-6R) antibody tocilizumab (TCZ) in the patients with refractory TA.
methods: Four patients with TA who had shown GC resistance received TCZ infusions (8mg/kg body weight) every four weeks for at least 18 times 
(range from 18 to 55). Clinical symptoms of disease activity, the levels of acute phase proteins such as C-reactive protein and serum amyloid A, and 
GC dosage necessary to maintain remission were prospectively assessed. CT and MRI scan were performed to monitor local inflammation. 
results: The mean duration of TCZ treatment was 22.2 times (range 18-55 times). All patients achieved a rapid normalization of the acute phase 
proteins and complete clinical response. Remarkably, predonisolone dosage could be reduced to a mean of 2.2mg/day (range 0-3 mg/day). All 
of the three patients who received TCZ for more than 2 years showed significant reduction in the thickened artery lesions. No relapse and no drug-
related side effects were noted in all patients. 
conclusions: In this small group of patients with refractory TA, treatment with TCZ was effective and well-tolerated. Further larger studies are 
required to confirm our findings.
